Two Sigma Investments, LP Rubius Therapeutics, Inc. Transaction History

Two Sigma Investments, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.14 - $0.31 $2,688 - $5,952	19,200 New	19,200 $3,000
Q2 2022 Aug 15, 2022	BUY	$0.79 - $5.98 $266,966 - $2.02 Million	337,932 Added 104.09%	662,593 $564,000
Q1 2022 May 16, 2022	BUY	$4.25 - $10.4 $160,199 - $392,017	37,694 Added 13.14%	324,661 $1.79 Million
Q4 2021 Feb 14, 2022	BUY	$9.68 - $17.74 $391,081 - $716,713	40,401 Added 16.39%	286,967 $2.78 Million
Q3 2021 Nov 15, 2021	BUY	$17.6 - $25.91 $1.72 Million - $2.54 Million	97,910 Added 65.86%	246,566 $4.41 Million
Q2 2021 Aug 16, 2021	BUY	$22.26 - $28.43 $3.31 Million - $4.23 Million	148,656 New	148,656 $3.63 Million
Q1 2021 May 17, 2021	SELL	$8.02 - $32.01 $166,455 - $664,367	-20,755 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$4.23 - $8.73 $111,401 - $229,913	-26,336 Reduced 55.93%	20,755 $158,000
Q3 2020 Nov 16, 2020	SELL	$4.65 - $6.25 $105,220 - $141,425	-22,628 Reduced 32.46%	47,091 $236,000
Q2 2020 Aug 14, 2020	SELL	$4.01 - $6.88 $80,127 - $137,476	-19,982 Reduced 22.28%	69,719 $417,000
Q1 2020 May 15, 2020	BUY	$3.74 - $9.84 $335,481 - $882,657	89,701 New	89,701 $399,000

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.